Legal & General Group
CGON icon

Legal & General Group’s CG Oncology CGON Stock Holding History

Legal & General Group’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85M Buy
40,062
+2,054
+5% +$134K ﹤0.01% 1826
2026
Q1 		$2.57M Sell
38,008
-7,139
-16% -$404K ﹤0.01% 1802
2025
Q4 		$1.87M Buy
45,147
+1,909
+4% +$79K ﹤0.01% 1996
2025
Q3 		$1.74M Sell
43,238
-1,116
-3% -$32.4K ﹤0.01% 2035
2025
Q2 		$1.15M Buy
44,354
+4,847
+12% +$117K ﹤0.01% 2192
2025
Q1 		$968K Buy
39,507
+10,245
+35% +$288K ﹤0.01% 2198
2024
Q4 		$839K Buy
29,262
+4,865
+20% +$166K ﹤0.01% 2300
2024
Q3 		$921K Buy
24,397
+5,262
+27% +$184K ﹤0.01% 2261
2024
Q2 		$604K Buy
19,135
+16,973
+785% +$588K ﹤0.01% 2351
2024
Q1 		$94.8K Buy
+2,162
New +$88.3K ﹤0.01% 2739

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Legal & General Group's CGON Position: Q2 2026 in Review

Legal & General Group increased its CG Oncology (CGON) stake by 5.4% in Q2 2026, buying an estimated $134K and bringing the position to 40,062 shares worth $2.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1826.

Legal & General Group first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Legal & General Group held 40,062 shares of CG Oncology worth $2.85M as of Q2 2026.
  • Legal & General Group bought 2,054 CG Oncology shares in Q2 2026, an estimated $134K.
  • CG Oncology made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1826 holding.
  • Legal & General Group first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.